D. E. Shaw & Co., Inc. Heron Therapeutics, Inc. Transaction History

D. E. Shaw & Co., Inc.

$98.6 Billion
Q2 2024

A detailed history of D. E. Shaw & Co., Inc. transactions in Heron Therapeutics, Inc. stock. As of the latest transaction made, D. E. Shaw & Co., Inc. holds 3,863,375 shares of HRTX stock, worth $7.69 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares

3,863,375

Previous 2,695,046 43.35%

Holding current value

$7.69 Million

Previous $7.47 Million 81.13%

% of portfolio

0.01%

Previous 0.01%

28 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	BUY	$2.32 - $3.86 $2.71 Million - $4.51 Million	1,168,329 Added 43.35%	3,863,375 $13.5 Million
Q1 2024 May 15, 2024	BUY	$1.71 - $3.06 $2.4 Million - $4.3 Million	1,404,049 Added 108.76%	2,695,046 $7.47 Million
Q4 2023 Feb 14, 2024	BUY	$0.54 - $1.82 $564,690 - $1.9 Million	1,045,724 Added 426.35%	1,290,997 $2.19 Million
Q3 2023 Nov 14, 2023	SELL	$0.97 - $1.8 $100,576 - $186,636	-103,687 Reduced 29.71%	245,273 $252,000
Q2 2023 Aug 14, 2023	SELL	$1.11 - $2.88 $413,055 - $1.07 Million	-372,122 Reduced 51.61%	348,960 $404,000
Q1 2023 May 15, 2023	SELL	$1.51 - $3.25 $99,656 - $214,493	-65,998 Reduced 8.39%	721,082 $1.09 Million
Q4 2022 Feb 14, 2023	SELL	$2.25 - $4.67 $253,104 - $525,332	-112,491 Reduced 12.5%	787,080 $1.97 Million
Q3 2022 Nov 14, 2022	SELL	$2.66 - $5.37 $1.9 Million - $3.84 Million	-715,411 Reduced 44.3%	899,571 $3.8 Million
Q2 2022 Aug 15, 2022	SELL	$2.3 - $6.29 $964,268 - $2.64 Million	-419,247 Reduced 20.61%	1,614,982 $4.51 Million
Q1 2022 May 16, 2022	BUY	$4.63 - $9.94 $3.17 Million - $6.8 Million	683,738 Added 50.63%	2,034,229 $11.6 Million
Q4 2021 Feb 14, 2022	SELL	$8.35 - $12.6 $680,007 - $1.03 Million	-81,438 Reduced 5.69%	1,350,491 $12.3 Million
Q3 2021 Nov 15, 2021	SELL	$10.13 - $15.0 $5.39 Million - $7.98 Million	-532,221 Reduced 27.1%	1,431,929 $15.3 Million
Q2 2021 Aug 16, 2021	SELL	$13.27 - $18.48 $3.23 Million - $4.5 Million	-243,240 Reduced 11.02%	1,964,150 $30.5 Million
Q1 2021 May 17, 2021	SELL	$14.49 - $20.72 $780,837 - $1.12 Million	-53,888 Reduced 2.38%	2,207,390 $35.8 Million
Q4 2020 Feb 16, 2021	BUY	$14.61 - $22.14 $2.46 Million - $3.73 Million	168,612 Added 8.06%	2,261,278 $47.9 Million
Q3 2020 Nov 16, 2020	SELL	$13.67 - $17.77 $352,357 - $458,039	-25,776 Reduced 1.22%	2,092,666 $31 Million
Q2 2020 Aug 14, 2020	SELL	$10.89 - $21.47 $2.25 Million - $4.44 Million	-206,661 Reduced 8.89%	2,118,442 $31.2 Million
Q1 2020 May 15, 2020	SELL	$10.23 - $24.56 $5.32 Million - $12.8 Million	-519,946 Reduced 18.28%	2,325,103 $27.3 Million
Q4 2019 Feb 14, 2020	BUY	$17.42 - $26.61 $21 Million - $32.1 Million	1,207,750 Added 73.76%	2,845,049 $66.9 Million
Q3 2019 Nov 14, 2019	BUY	$16.36 - $21.39 $4.34 Million - $5.67 Million	265,008 Added 19.31%	1,637,299 $30.3 Million
Q2 2019 Aug 14, 2019	SELL	$16.93 - $26.22 $1.68 Million - $2.6 Million	-99,305 Reduced 6.75%	1,372,291 $25.5 Million
Q1 2019 May 15, 2019	BUY	$23.15 - $28.34 $9.67 Million - $11.8 Million	417,588 Added 39.62%	1,471,596 $36 Million
Q4 2018 Feb 14, 2019	BUY	$22.03 - $32.01 $10.4 Million - $15.1 Million	473,127 Added 81.45%	1,054,008 $27.3 Million
Q3 2018 Nov 14, 2018	BUY	$30.0 - $40.85 $4.28 Million - $5.83 Million	142,648 Added 32.55%	580,881 $18.4 Million
Q2 2018 Aug 14, 2018	SELL	$26.4 - $42.0 $14.2 Million - $22.6 Million	-537,780 Reduced 55.1%	438,233 $17 Million
Q1 2018 May 15, 2018	BUY	$18.43 - $28.8 $8.85 Million - $13.8 Million	480,381 Added 96.92%	976,013 $26.9 Million
Q4 2017 Feb 14, 2018	BUY	$14.8 - $18.85 $3.78 Million - $4.82 Million	255,457 Added 106.36%	495,632 $8.97 Million
Q3 2017 Nov 14, 2017	BUY	$14.65 - $16.85 $3.52 Million - $4.05 Million	240,175	240,175 $3.88 Million

Others Institutions Holding HRTX

# of Institutions

198

Shares Held

129M

Call Options Held

94.7K

Put Options Held

148K

View Full List

About HERON THERAPEUTICS, INC.

Ticker HRTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 118,774,000
Market Cap $236M
Description
Heron Therapeutics, Inc., a biotechnology company, engages in developing treatments to address unmet patient needs. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single a...

More about HRTX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of D. E. Shaw & Co., Inc., based on Form 13F filings with the SEC.

News

Stay updated on D. E. Shaw & Co., Inc. with notifications on news.

Account